Most importantly, a pharmacological approach based on daily dosing of GSK126, a clinically relevant Ezh2 inhibitor, also promoted a moderate and significant tumor growth inhibition and extension in survival (Fig. 2 E). The gene discussed is EZH2; the disease is neoplasm.